Added to YB: 2026-05-05
Pitch date: 2026-05-01
RCKT [neutral]
Rocket Pharmaceuticals, Inc.
+1.69%
current return
Author Info
The Pharma Fox is a PhD biochemist & independent biotech investor. Sign up for the newsletter.
Company Info
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Market Cap
$379.7M
Pitch Price
$3.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.00
P/E
-1.73
EV/Sales
N/A
Sector
Biotechnology
Category
turnaround
Outfoxed Issue 1: Rocket Pharmaceuticals: Houston, We Have a Narrative Problem
RCKT (overview): Analysts claim KRESLADI approval de-risks platform, but wrong - it validated LV platform Rocket is abandoning, not AAV pipeline driving future value. Pivoted from low-risk/low-reward LV to high-risk/high-reward cardio AAV: RP-A501 (Danon) had patient death & hold, uses AAV9 (RGNX's tumor vector); RP-A601 (PKP2-ACM, $2.6B peak) uses AAVrh74 (Sarepta's toxic vector). PRV sale gave $180M but $368M cash vs $190M burn + KRESLADI launch obligations = tight runway. Strong AAV data but faces same sector risks as NGNE, RGNX, SRPT. Watchlist until de-risking narrative vs valuation clarifies. Author prefers LXEO: better vector (AAVrh10), FDA-aligned trials, 27 pts dosed with no SAEs, J&J Impella partnership, competing PKP2 program w/ 10 pts vs RCKT's 3.
Read full article (14 min)